The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.80
Ask: 3.84
Change: 0.09 (2.43%)
Spread: 0.04 (1.053%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.71
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Argentina approves Harpin as a seed treatment

1 Sep 2021 07:00

RNS Number : 1012K
Plant Health Care PLC
01 September 2021
 

RNS

1 September 2021

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Argentina approves Harpin ab for use as a seed treatment in Corn and Soybeans

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce the registration approval of Harpin ab for use as a seed treatment in Argentina.

 

The regulatory process in Argentina for agricultural products involves detailed review and approval by Senasa, the Country's National Food Safety and Quality Service, which classified Harpin ab as a biostimulant organic-chemical fertilizer. This confirms the Argentinian government's commitment to promoting cost effective, sustainable and safe products.

 

Highlights

· Corn and soybeans are the first crops to receive regulatory approval for Harpin ab in Argentina.

· Argentina has 24 million hectares (60 million acres) of corn and soybeans planted in the current season. Growers spent more than $100m on soybean seed treatments in Argentina in the most recent season. The size of the biological market in soybeans is growing rapidly and was about $75m in 2021.

· The Company is currently working with multiple organizations that are evaluating Harpin ab and will select in-country distribution partners in due course.

 

Harpin ab works by triggering the plant's own self defense systems, leading to a robust physiological response, in a manner similar to vaccinations in humans. The plant responds with improved crop quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased yield. Being a biological product, Harpin αβ has a very favorable human and environmental safety profile.

 

Chris Richards, CEO of Plant Health Care, said: ‟Harpin ab registration in Argentina is key to the further expansion of Harpin ab use into large row crop markets."

 

 

For further information, please contact:

 

Plant Health Care plc- Tel: +1 919 926 1600

Chris Richards, CEO

 

Arden Partners plc - Nomad & Joint Broker Tel: +44 (0) 20 7614 5900

John Llewellyn-Lloyd / Antonio Bossi

 

Cenkos Securities plc - Joint Broker Tel: +44 (0) 20 7391 8900

Neil McDonald / Peter Lynch

 

Vox Markets - Digital investor relations Tel: +44 (0) 7866 384707

Paul Cornelius / Kat Perez

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDLFDSEFSELA
Date   Source Headline
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement
28th Nov 20187:00 amRNSNew Technology Update
21st Nov 20187:00 amRNSPlant Health Care ProAct® Wins Top Industry Award
19th Nov 20187:00 amRNSPlant Health Care to present at Mello London

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.